Pramipexole ER vs IR and Food Effect in Healthy Males

Phase 1, randomised, double-blind trial of pramipexole in Parkinson's disease (PD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ=0-24h at Day 5, Maximum measured concentration of the analyte in plasma at steady state at Day 5 and 1 more. Started Apr 2006; status: completed.